Medtronic announces first patient implants of investigational implantable tibial neuromodulation therapy for bladder incontinence

Titan 2 pivotal study to evaluate implantable tibial neuromodulation (tnm) device to help expand patient access to advanced therapy dublin, march 24, 2022 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today announced the first patient implants in the titan 2 pivotal study that will evaluate the safety and efficacy of medtronic's investigational implantable tibial neuromodulation (tnm) device in people with overactive bladder (oab). the minimally invasive technology stimulates the posterior tibial nerve near the ankle, transmitting electrical impulses that regulate neural activity of the bladder.
MDT Ratings Summary
MDT Quant Ranking